BioSpace News Archive

Pharm Country

First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma

Regeneron Pharmaceuticals, Inc. announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma.

December 8, 2019
·
12 min read
Drug Development

Cerevel Therapeutics Announces Phase 1 Results for CVL-865, a Novel α2/3/5-subtype GABAA Positive Allosteric Modulator in Development to Treat Epilepsy

Cerevel Therapeutics announced results of a Phase 1 dose-escalation clinical trial1 evaluating the safety, tolerability and pharmacokinetics of multiple repeated doses of CVL-865 in healthy volunteers.

December 8, 2019
·
6 min read
Drug Development

Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Treatment of Dravet Syndrome

STK-001 showed distribution throughout the brain after a single intrathecal injection; Target engagement and increased Nav1.1 protein expression were observed throughout the cortex

December 8, 2019
·
8 min read
Genetown

Syros Presents on Identification of Novel Fetal Hemoglobin Repressor as Part of Broader Drug Discovery Program in Sickle Cell Disease at 61st Annual ASH Meeting

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced that it has discovered and validated a novel fetal hemoglobin repressor, Nuclear Factor I X, using its gene control platform.

December 8, 2019
·
5 min read
Drug Development

Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies

Interim Results Demonstrate Good Tolerability and Clinical Response in Patients with Relapsed/Refractory PTCL and CTCL

December 8, 2019
·
6 min read
Drug Development

Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 “Process B” for Fanconi Anemia at 61st American Society of Hematology Annual Meeting

US Phase 1 Trial Establishes Feasibility of Commercial “Process B” Vector/Cell Manufacturing in FA

December 8, 2019
·
8 min read
Drug Development

Beam Therapeutics Presents Preclinical Data for Complementary Base Editing Approaches for Hemoglobinopathies at ASH 2019

HPFH program achieves in vivo proof of concept of long term engraftment with >90% base editing maintained after 16 weeks

December 8, 2019
·
3 min read
Drug Development

Viracta Announces Positive Phase 1b/2 Data Presented at Oral Presentation on Lead Program for Epstein-Barr Virus (EBV)-associated Relapsed/Refractory Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting

Phase 1b Overall Objective Response Rate (ORR) of 56% Including 28% Complete Response (CR)

December 8, 2019
·
6 min read
Drug Development

Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology (ASH) Annual Meeting

7/9 (77.8%) evaluable subjects exhibited clinical benefit, including three complete responses and two partial responses

December 8, 2019
·
8 min read
Pharm Country

Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology (ASH) Annual Meeting

Heavily pre-treated patients with chronic lymphocytic leukemia receiving liso-cel achieved durable complete responses, including undetectable minimal residual disease

December 8, 2019
·
11 min read